

## **OSP Community Conference 2024 Agenda**

## Day 1 - Monday October 7, 2024

11:30 - 12:45	Registration & Networking & Snacks (finger food lunch)				
12:45 - 12:50	Welcome & Keynote				
12:45 - 12:55	Birgit Schoeberl (Novartis): Welcome from the Host				
12:55 - 13:00	Stephan Schaller (ESQlabs): Welcome from the OSP Management Team				
13:00 - 13:30	KEYNOTE: Jörg Lippert (Bayer) & Stephan Schaller (ESQlabs): The Roots and the Leaves of the OSP Suite				
<b>13:30 - 14:30</b> (15' + 5' Q&A)	Session I: Physiologically Based Biopharmaceutics Modelling (PBBM) Chairs: André Dallmann (Bayer), Erik Sjögren (Pharmetheus)				
13:30 - 13:50	Mariana Guimaraes Sa Correia (ESQlabs): Leveraging OSP for developing dissolution safe-space through IVIVC and VBE workflows: a qualification perspective				
13:50 - 14:10	Paul Vrenken (National and Kapodistrian University of Athens): Extending the OSP Oral Absorption Toolbox: An End-to-End PBBM Approach				
14:10 - 14:30	<b>Fabian Winter (AbbVie):</b> Combination of in-vitro and in-silico tools for biopharmaceutical risk assessment in drug product development				
14:30 - 15:00	NETWORKING Coffee				
<b>15:00 - 16:00</b> (15' + 5' Q&A)	Session II: In Vitro-In Vivo Extrapolation Chairs: Donato Teutonico (Sanofi), Tobias Kanacher (Pharmetheus)				
15:00 - 15:20	Susana Proença (ESQlabs): Towards an OSP IVIVE Toolbox				
15:20 - 15:40	Choi Siak-Leng (Sanofi): Organ-on-a-Chip (OoC) Digital Twins for Estimating Small Molecules' Human Hepatic Clearance and PK Profiles				
15:40 - 16:00	Denise Feick (Sanofi): Prediction of human fraction absorbed from in vitro Caco-2 permeability – are we there yet?				
	there yet?				

<b>16:00 - 17:30</b> (15' + 5' Q&A)	Session III: Perspectives on the use of PBPK in regulatory submission Chairs: Stephan Schaller (ESQlabs), Ibrahim Ince (Boehringer Ingelheim)				
16:00 - 16:20	Flora Musuamba (EMA, U Namur): Risk-based approach for model assessment				
16:20 - 16:40	<b>Masanobu Sato (Boehringer Ingelheim):</b> Exploring Recent Trends in PBPK Applications in New Drug Approvals in Japan: Regulations and Reviews by PMDA				
16:40 - 17:00	<b>Pieter J Colin (EMA, UMC Groningen):</b> EMA review of assessments of PBPK models from regulatory submissions				
17:00 - 17:20	Hao Zhu (Private, Key Opinion Leader in Mechanistic Modeling): Use of mechanistic modeling to support new drug development and decision-making				
17:20 - 17:30	Regulatory Applications with OSP: Open Discussion & Exchange				
17:30 - 18:00	Session IV: Integrated PBPK-PD/QSP modeling				
(20' + 10' Q&A)	Chairs: Henrik Cordes (Sanofi), Stephan Schaller (ESQlabs)				
17:30 - 18:00	Pavel Balazki (ESQlabs): Introducing OSMOSES: Modularization and Qualification of complex PB-QSP models with OSP version 12				
18:30 - 24:00	Dinner @ Volta Bräu (open end, INCLUDED IN REGISTRATION)				

# Day 2 - Tuesday October 8, 2024

<b>08:30 - 09:10</b> (15' + 5' Q&A)	Session V: Drug-Drug Interaction Modeling Chairs: Alexander Staab (Boehringer Ing.), Marylore Chenel (Pharmetheus)			
08:30 - 08:50	Thomas Wendl (Bayer): PBPK DDI Network Qualification and Regulatory Application			
08:50 - 09:10	Sheila Peters (Boehringer Ingelheim): Optimal Use of Static and Dynamic Models for DDI Assessment along the Value Chain			
<b>09:10 - 10:10</b> (15' + 5' Q&A)	Session VI: PBPK Best Practice & Introduction to the ICH MIDD Guidance Chairs: Rolf Burghaus (Bayer), Jan Schlender (Novartis)			
09:10 - 09:30	Nicolas Frey (Roche): ICH M15 Model Informed Drug Development – Steps Toward Harmonized Guidance			
09:30 - 09:50	Jan Schlender (Novartis): Best Practices in PBPK for the OSP Suite Community			
09:50 - 10:10	Abdullah Hamadeh (University of Waterloo): The FDA Model Master File: Standardization of M&S practices to support the development and approval of dermatological products			
10:10 - 10:40	NETWORKING Coffee			
10:40 - 11:40	Session VII: Large Molecules Modeling Chairs: Wilbert de Witte (ESQlabs), Christoph Niederalt (Bayer)			
10:40 - 11:00	Wilbert de Witte (ESQlabs): PBPK-QSP modelling of FcRn Inhibitors and the use of the PK-Sim FcRn Model			
11:00 - 11:40	Erik Sjögren (Pharmetheus) & Salih Benamara (Sanofi): Modeling Subcutaneous Absorption & Immunogenicity of Large Molecules			

11:40 - 12:40	Session VIII: Special Populations in the OSP Suite Chairs: Ibrahim Ince (Boehringer Ingelheim), André Dallmann (Bayer)			
11:40 - 12:00	André Dallmann (Bayer): Modeling Motherhood I: Pregnancy PBPK in the Era of Personalized Medicine			
12:00 - 12:20	Kathleen Job (University of Utah): Modeling Motherhood II: Pregnancy PBPK for Asthma			
12:20 - 12:40	Julia Macente & Nina Nauwelaerts (KU Leuven): Modeling Motherhood III: Lactation PBPK modeling			
12:40 - 13:00	Annika Schneider (Bayer): PBPK Modeling for Hepatically Impaired Patients			
13:00 - 14:00	NETWORKING & Lunch			
14:00 - 15:00	Session IX: Community Engagement – OSP Suite Qualification & Release Chairs: Donato Teutonico (Sanofi), Rolf Burghaus (Bayer)			
14:00 - 14:20	Stephan Schaller (ESQlabs): OSP Community Engagement & Dissemination			
14:20 - 15:00	Juri Solodenko (Bayer): OSP Software Release Management and (Re-)Qualification Framework			
15:00 - 15:30	NETWORKING coffee			
15:30 - 16:00	Session X: OSP community building, funding, and management Chairs: Alexander Staab (Boehringer Ingelheim), Andreas Kovar (Sanofi)			
15:30 - 15:45	Stephan Schaller (ESQlabs): Building and Funding a Sustainable Community for the OSP Suite			
15:45 - 16:00	Open Discussion & Exchange			
16:00 - 16:30	Participant Feedback on Conference, Evaluation			
16:30 +	Departure			

#### Location

#### <u>Novartis Campus:</u> Frank O. Gehry building, Fabrikstrasse 15, 4056 Basel, Switzerland

#### **Hotel Recommendations**

#### Near Novartis Campus:

The Novartis Campus is right at the French border and, hence, hotels in Saint Louis are a budget option. Here are a few options in walking distance:

Aparthotel Adagio Access Saint Louis Bâle, Saint-Louis – 700 m Hôtel et Spa La Villa K – Basel Airport, Saint-Louis – 1.7 km HÔTEL D, Blumenrain 19, 4051 Basel (via Tram 11) – 1.8 km Ibis Aéroport Bâle Mulhouse, Saint-Louis – 2 km

### **Organizing Committee**

Henrik Cordes, Sanofi	Donato Teutonico, Sanofi	Stephan Schaller, ESQlabs	Ibrahim Ince, Boehringer Ingelheim
Wilbert de Witte,	Lars Kupfer,	André Dallmann,	Jan Schlender,
ESQlabs	RWTH Aachen	Bayer	Novartis

#### **Sponsors**







Silver 

(Become a sponsor)



Bronze (Become a sponsor)







#### Contact

info@clsfoundation.org

